ProtAffin AG Granted Patent in EU for Lead Anti-inflammatory Product PA401
Whereas wild-type chemokines are over-expressed in many chronic and acute inflammatory diseases, ProtAffin has developed anti-inflammatory variants of IL-8 with increased affinity for heparin-like glycan structures found on inflamed endothelium. These anti-inflammatory products do not activate chemokine receptors found on leukocytes.
Dr. Jason Slingsby, CEO of ProtAffin commented: “We are very pleased that the European Patent Office has granted us claims protecting our lead anti-inflammatory product PA401, as well as other anti-inflammatory variants of IL-8. This is an important commercial step for us as we seek to develop and commercialise PA401 for a number of chronic and acute diseases in the world’s major pharmaceutical markets. PA401 represents a novel class of biological product which disrupts protein-glycan interactions which drive inflammation in a number of diseases with serious unmet medical need.”
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.